Tenet Healthcare Corp (NYSE:THC) disclosed that director Nadja West sold 1,152 shares of common stock on Sept. 2, 2026, for a total of $298,137. The transaction, filed with the SEC on Sept. 3, was executed at $258.80 per share. After the sale, West retained a direct holding of 23,653 shares.
At the time of the filing, Tenet stock was trading around $263.49, close to its 52‑week high of $283.05 and delivering a 37% return over the past year. The market's fair‑value estimate from InvestingPro stands at $292, with a price‑to‑earnings multiple of 10.27.
Tenet reported second‑quarter 2026 results that beat consensus forecasts. Adjusted earnings were $6.12 per share, well above Wall Street's $4.23 estimate, and revenue reached $5.63 billion, exceeding the $5.43 billion forecast. Following the strong performance, the company raised its full‑year outlook.
Analyst sentiment turned more bullish after the earnings release. UBS lifted its price target to $308, citing an improved earnings outlook and higher adjusted EBITDA projections for 2026‑27. Guggenheim increased its target to $283, pointing to the hospital business strategy. Raymond James raised its target to $275, highlighting Tenet's outperformance relative to peers. Cantor Fitzgerald also upgraded its target to $270, noting the company's ability to exceed investor expectations through guidance adjustments.
The insider sale and the upbeat earnings report occurred concurrently, underscoring a period of heightened investor interest in Tenet Healthcare.
